Abstract
Immunity against genital Herpes Simplex Virus 2 (HSV-2) infection is dependent on local memory immune responses in the genital tract. Oral immunisation can induce mucosal immune responses in the genital tract but has not been tested against viral STIs. Here we describe the mucosal immune responses elicited by an oral vaccine that protects mice against intravaginal challenge from lethal HSV-2 infection. Control of HSV-2 was attributed to HSV-2-specific IgG and IgA in the genital mucosa together with CD4 and CD8 T cells recruited to the genital epithelia. Furthermore, combining this vaccine with vaginal application DNFB to induce transient local inflammation led to the recruitment of CD8 tissue resident memory cells in the genital epithelia that controlled new infection with HSV-2. Thus, this represents the first oral vaccine that can protect mice against lethal intravaginal HSV challenge.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
